Ignoring steroids by Van Epps, Heather L.
IN THIS ISSUE | The Journal of Experimental Medicine  3
A new study by Ito and colleagues on page 7 may help 
explain why patients with a severe lung disease called chronic 
obstructive pulmonary disease (COPD) fail to respond to 
steroid treatment. Ito and colleagues show that steroids 
require the enzyme HDAC2 (histone deacetylase 2) to block the 
inflammatory transcription factor NF-κB. In patients with COPD, 
HDAC2 activity is reduced, rendering cells impervious to the 
soothing effects of steroids.
Steroids called glucocorticoids (GCs) are powerful 
antiinflammatory drugs used to treat chronic inflammatory 
disorders such as asthma and inflammatory bowel disease. But 
these drugs don’t work in patients with COPD—a chronic 
inflammatory disease of the lungs linked to cigarette smoking.
When working properly, GCs calm inflammation in two ways. 
They bind to the cytoplasmic glucocorticoid receptor (GR), which 
then binds to NF-κB and prevents it from activating 
inflammatory gene expression. At high concentrations, GCs also 
induce the expression of HDAC proteins.
Consistent with the induction of HDAC expression in 
antiinflammatory responses, this group had previously shown 
that patients with more severe COPD had decreased 
expression of HDAC2, probably due to oxidative damage to 
the enzyme inflicted by cigarette smoke. HDAC2 is most well-
known for plucking acetyl groups from histones, thus 
preventing the transcriptional machinery from binding to 
chromatin. But now Ito and colleagues find that HDAC2 also 
deacetylates GRs. GRs are acetylated in response to steroid 
binding, but must be deacetylated by HDAC2 to allow them to 
block NF-κB–driven inflammation.
Overexpressing HDAC2 in macrophages from patients with 
COPD restored GC-induced suppression of NF-κB–driven cytokine 
production. These data not only identify GR as the first 
nonhistone target for HDAC2, but also suggest that strategies 
aimed at increasing HDAC2 activity, combined with steroids, 
might be useful for treating patients with COPD. 
Glucocorticoid receptors must be deacetylated by HDAC2 to block 
NF-κB-driven gene expression.
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Interferon (IFN)-α gives macrophages the upper 
hand against HIV, according to a study on page 
41. Peng and colleagues show that the cytokine 
IFN-α enhances the expression of the RNA-ed-
iting enzyme APOBEC3G, which mutates HIV 
DNA, thus triggering its degradation.
APOBEC3G is a close relative of the B 
cell–specific protein AID (activation-induced 
cytidine deaminase), which mutates immuno-
globulin DNA to generate high affinity anti-
bodies. APOBEC3G—which may have 
evolved as a regulator of endogenous retrovi-
ruses—recently emerged as an inhibitor of HIV 
replication in T cells, owing to its propensity to 
mutate retrotranscribed viral DNA. But HIV 
effectively counters this defense with the Vif 
protein, which binds to APOBEC3G and tar-
gets it for proteasomal degradation.
Boosting cellular levels of APOBEC3G 
might be an effective way to combat the de-
structive effects of Vif, but no APOBEC3G-
inducing factors had been identified. Now, 
Peng and colleagues show that IFNα—a 
known inhibitor of HIV replication—activates 
an IFN-responsive element in the APO-
BEC3G promoter in macrophages, thus driv-
ing APOBEC3G synthesis and overwhelming 
Vif’s capacity to degrade the protein.
But endogenous IFN-α, which is pro-
duced during viral infection, does not curtail 
HIV infection in vivo. This finding might be 
explained by the fact that T cells—the other 
major cell type targeted by HIV—do not ap-
pear to induce APOBEC3G expression in 
response to IFN-α. Besides investigating 
why the signal doesn’t get through to T cells 
(which express IFN receptors), the authors 
are now examining whether APOBEC3G 
expression or activity differs in myeloid cells 
that are resistant to HIV infection. Indeed, a 
recent study showed that the enzyme restricts 
HIV replication in resting T cells but be-
comes mired in an enzymatically inactive 
protein–RNA complex upon T cell activa-
tion, possibly explaining why HIV preferen-
tially replicates in activated T cells. 
The cellular protein APOBEC3G 
disrupts HIV replication 
when incorporated into new 
virions (shown budding 
from a macrophage).
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